Functional Treatment Planning Utilizing 18-FDGal PET/CT in SBRT for Liver Metastases

University of Aarhus

Status and phase: Unknown; Phase 2

Conditions: Liver Metastases

Treatments: Other: measuring liver function by 18-FDGal PET/CT

Study type: Interventional

Funder types: Other

Identifiers

NCT01861873

210982

Details and patient eligibility

About

Background: Anatomical (traditional) stereotactic body radio therapy(SBRT) treatment planning assumes homogenous distribution of function in the normal liver tissue. In functional treatment planning, additional information on distribution of the function derived from functional imaging of normal tissue is taken into account. by functional treatment planning it becomes possible to prioritize and spare the best functioning part of an organ.

Aim: To test whether functional treatment planning based on 18-FDGal PET/CT may spare the best functioning liver tissue.

Endpoints: Reduction in hepatic systemic clearance (K) in the dynamic 18-FDGal PET/CT scan one month after SBRT compared to the baseline status in sub-volumes recieving 15 Gy or higher. Secondly, the investigators will evaluate the toxicity to SBRT by a toxicity scoring system that includes biochemical measures as well as symptomatic scores.

Enrollment: 28 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Performance status >2
• liver metastases refereed for SBRT

Exclusion criteria

• pregnancy
• claustrophobia

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

28 participants in 1 patient group

liver metastases

Other group

Description:

measuring liver function by PET/CT at patients where SBRT is planned for liver metastases

Treatment:

Other: measuring liver function by 18-FDGal PET/CT